News | June 29, 2022
Glenmark Pharmaceuticals expand its OTC portfolio
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
First and only PARP inhibitor to improve invasive disease-free survival in patients
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
Most recently, she served as chief human resources officer at Vyripharm Enterprises.
Subscribe To Our Newsletter & Stay Updated
